June 2024
162 articles-
Jun 27 · 23:18Biotechnology Daily
With first MASH drug due for FDA nod, Ionis says me too with phase 2 data
-
Jun 27 · 23:18Biotechnology Daily
As Crinetics nears FDA run for growth disease drug, a phase 2 test makes the case for carcinoid syndrome, too
-
Jun 27 · 23:16Biotechnology Daily
After crunching 70k 'trip reports', Mindstate looks to test first AI-derived psychedelic on humans
-
Jun 27 · 23:15Biotechnology Daily
Mallinckrodt, Silence collab to go quiet, but a phase 2 cardiovascular win speaks loudly for the biotech
-
Jun 27 · 23:14Bio Business News
J&J's John Reed takes home $20M-plus payday in his first year helming pharma R&D team
-
Jun 27 · 23:08Bio Business News
Almirall signs yes-nonsense skin disease deal with Eloxx for $3M upfront
-
Jun 27 · 23:07Bio Business News
Sanofi shutting down R&D site at UK biotech hub, displacing 90 workers
-
Jun 27 · 23:05Bio Business News
Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront
-
Jun 26 · 22:24Biotechnology Daily
Geron faces uphill battle at FDA meeting as agency questions benefit-risk profile of imetelstat
-
Jun 26 · 22:21Biotechnology Daily
FDA hands Class I label to Abbott HeartMate LVAD software recall
-
Jun 26 · 22:19Biotechnology Daily
To boldly go back: Lilly charts 2nd space trip in 4 months, this time with chronic disease tests
-
Jun 26 · 22:18Biotechnology Daily
Mustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trial
-
Jun 26 · 22:15Bio Business News
In conversation with Medtronic's Frank Chan, head of its off-again, on-again acute care and monitoring division
-
Jun 26 · 22:11Bio Business News
Fortrea sells pair of businesses to private equity firm to become 'pure-play' CRO
-
Jun 26 · 22:09Bio Business News
A founder's quest for drug to treat his own hand condition kicks off with positive mouse data
-
Jun 26 · 22:08Bio Business News
Patient Square Capital aims to roll up NanoString assets with $220M bid
-
Jun 25 · 23:39Biotechnology Daily
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
-
Jun 25 · 23:37Biotechnology Daily
BioVie cuts 'most de-risked program,' will seek partners for phase 3-ready ascites program
-
Jun 25 · 23:36Biotechnology Daily
Know Labs posts accuracy data comparing its noninvasive glucose monitor to hospital meters
-
Jun 25 · 23:34Biotechnology Daily
After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory
-
Jun 25 · 23:32Bio Business News
FDA hands Class I label to Medtronic cerebrospinal fluid tubing recall
-
Jun 25 · 23:31Bio Business News
Sensorion's hearing loss drug reaches target in comeback story after phase 2 failure
-
Jun 25 · 23:29Bio Business News
Merck bets up to $1B on Pearl's 'smart' biomaterial jewels as biotech begins to raise fresh funds
-
Jun 25 · 23:28Bio Business News
BMS checks out of next-gen Yervoy pact with CytomX, taking $300M in biobucks with it